



REINSURANCE **HOT NEWS**

December 9, 2025

AHCCCS is pleased to announce the addition of Forzinity and Zevaskyn to the High-Cost Specialty Drug Reinsurance (BIO) effective 01/01/2026:

Forzinity - (Elamipretide) - Indicated to Improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

Zevaskyn - (Prademagene Zamikeracel) - Indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.

Here is the Link to the Updated High-Cost Specialty Drug List:
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>